{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:6372"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:6372","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Chemokine receptors as therapeutic targets in liver disease","abstract":"There is an urgent need for new insights into the pathology of liver disease to underpin new therapeutic approaches. Chemokines and their receptors are central to the development of liver inflammation. I investigated liver disease using ex-vivo human tissue to analyse gene and protein expression in liver and the nature of inflammation. Animal models of liver disease were used to investigate the effects of manipulating the chemokine system. In Non-Alcoholic Fatty Liver Disease (NAFLD) expression of CCL2 is increased. A subset of monocytes expressed CD11c and CD206, and maintained CCR2 expression in NAFLD. The frequency of this subset was associated with insulin resistance. In animal models of NAFLD, antagonism of CCR2 improved liver disease. In mouse models of acute liver failure (ALF), expression of CCL25 was an early response after injury, a phenomenon also seen in human ALF. Influx of CCR9\\(^+\\) monocytes was a corresponding early event in murine liver. Prophylactic administration of a CCR9 antagonist reduced liver injury and macrophage infiltration. CXCR6 has contrasting effects in murine liver injury: damaging in acute injury but protective in chronic injury. In human liver CXCR6 promotes infiltration Natural Killer cells, particularly in primary biliary cirrhosis, but may also promote regeneration of hepatocytes.","abstract_html":"There is an urgent need for new insights into the pathology of liver disease to underpin new therapeutic approaches. Chemokines and their receptors are central to the development of liver inflammation. I investigated liver disease using ex-vivo human tissue to analyse gene and protein expression in liver and the nature of inflammation. Animal models of liver disease were used to investigate the effects of manipulating the chemokine system. In Non-Alcoholic Fatty Liver Disease (NAFLD) expression of CCL2 is increased. A subset of monocytes expressed CD11c and CD206, and maintained CCR2 expression in NAFLD. The frequency of this subset was associated with insulin resistance. In animal models of NAFLD, antagonism of CCR2 improved liver disease. In mouse models of acute liver failure (ALF), expression of CCL25 was an early response after injury, a phenomenon also seen in human ALF. Influx of CCR9<span class=\"etd-inline-math\"><sup>+</sup></span> monocytes was a corresponding early event in murine liver. Prophylactic administration of a CCR9 antagonist reduced liver injury and macrophage infiltration. CXCR6 has contrasting effects in murine liver injury: damaging in acute injury but protective in chronic injury. In human liver CXCR6 promotes infiltration Natural Killer cells, particularly in primary biliary cirrhosis, but may also promote regeneration of hepatocytes.","abstract_has_math":true,"creators":["Parker, Richard"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015-12","date_published":"2015-12","updated_at":"2026-11-19T09:28:51Z","subjects":["RC Internal medicine"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/6372/5/Parker15PhD_Redacted.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A6372","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["mrc","other"]},{"key":"dc:creator","label":"Author","values":["Parker, Richard"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2015-12"]},{"key":"dc:date.issued","label":"Date","values":["2015-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","School of Immunity and Infection"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/6372/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC Internal medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/6372/5/Parker15PhD_Redacted.pdf","http://etheses.bham.ac.uk//id/eprint/6372/2/Decl_IS_Parker15PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["There is an urgent need for new insights into the pathology of liver disease to underpin new therapeutic approaches. Chemokines and their receptors are central to the development of liver inflammation. I investigated liver disease using ex-vivo human tissue to analyse gene and protein expression in liver and the nature of inflammation. Animal models of liver disease were used to investigate the effects of manipulating the chemokine system. In Non-Alcoholic Fatty Liver Disease (NAFLD) expression of CCL2 is increased. A subset of monocytes expressed CD11c and CD206, and maintained CCR2 expression in NAFLD. The frequency of this subset was associated with insulin resistance. In animal models of NAFLD, antagonism of CCR2 improved liver disease. In mouse models of acute liver failure (ALF), expression of CCL25 was an early response after injury, a phenomenon also seen in human ALF. Influx of CCR9\\(^+\\) monocytes was a corresponding early event in murine liver. Prophylactic administration of a CCR9 antagonist reduced liver injury and macrophage infiltration. CXCR6 has contrasting effects in murine liver injury: damaging in acute injury but protective in chronic injury. In human liver CXCR6 promotes infiltration Natural Killer cells, particularly in primary biliary cirrhosis, but may also promote regeneration of hepatocytes."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["Chemokine receptors as therapeutic targets in liver disease"]}]}],"canonical_facts":{"dc:contributor.sponsor":["mrc","other"],"dc:creator":["Parker, Richard"],"dc:date":["2015-12"],"dc:date.issued":["2015-12"],"dc:description.abstract":["There is an urgent need for new insights into the pathology of liver disease to underpin new therapeutic approaches. Chemokines and their receptors are central to the development of liver inflammation. I investigated liver disease using ex-vivo human tissue to analyse gene and protein expression in liver and the nature of inflammation. Animal models of liver disease were used to investigate the effects of manipulating the chemokine system. In Non-Alcoholic Fatty Liver Disease (NAFLD) expression of CCL2 is increased. A subset of monocytes expressed CD11c and CD206, and maintained CCR2 expression in NAFLD. The frequency of this subset was associated with insulin resistance. In animal models of NAFLD, antagonism of CCR2 improved liver disease. In mouse models of acute liver failure (ALF), expression of CCL25 was an early response after injury, a phenomenon also seen in human ALF. Influx of CCR9\\(^+\\) monocytes was a corresponding early event in murine liver. Prophylactic administration of a CCR9 antagonist reduced liver injury and macrophage infiltration. CXCR6 has contrasting effects in murine liver injury: damaging in acute injury but protective in chronic injury. In human liver CXCR6 promotes infiltration Natural Killer cells, particularly in primary biliary cirrhosis, but may also promote regeneration of hepatocytes."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/6372/5/Parker15PhD_Redacted.pdf","http://etheses.bham.ac.uk//id/eprint/6372/2/Decl_IS_Parker15PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","School of Immunity and Infection"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/6372/"],"dc:subject":["RC Internal medicine"],"dcterms:accessrights":["public","staffonly"],"dc:title":["Chemokine receptors as therapeutic targets in liver disease"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:28:51Z"}